Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Kenneth S HershonRalf Rosskamp

Abstract

To present the findings in a randomized, parallel-group study, comparing once-daily insulin glargine with twice-daily NPH insulin in patients with type 1 diabetes previously treated with multiple daily injections of basal and regular insulin. Of 394 patients with type 1 diabetes treated for up to 28 weeks, 195 received insulin glargine and 199 received NPH insulin, in addition to preprandial regular insulin. Glycemic control and hypoglycemic episodes were assessed. A greater mean decrease in fasting blood glucose (FBG) was achieved at endpoint with insulin glargine than with NPH insulin (-21 mg/dL versus -10 mg/dL [-1.17 mmol/L versus -0.56 mmol/L]; P = 0.015), and a greater percentage of patients treated with insulin glargine reached the target FBG (32.6% versus 21.3%; P = 0.015). Similar percentages of patients in both treatment groups achieved glycosylated hemoglobin values of 7.0% or less at endpoint (insulin glargine, 35.8%; NPH insulin, 35.4%). After the 1-month titration phase, the percentage of patients who reported at least one symptomatic hypoglycemic event confirmed by a blood glucose value of less than 50 mg/dL (2.8 mmol/L) was significantly lower with insulin glargine than with NPH insulin (73.3% versus 81.7%; P = ...Continue Reading

References

Mar 1, 1992·Diabetologia·I Swenne
Jul 1, 1994·Diabetes Care·P E CryerH Shamoon
Dec 1, 1993·Diabetes Care·P E Cryer
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Jul 9, 1999·Biopolymers·H Berchtold, R Hilgenfeld
Dec 28, 2002·Diabetes Care·UNKNOWN American Diabetes Association
May 8, 2003·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·M Massi BenedettiM Ziemen

❮ Previous
Next ❯

Citations

Oct 26, 2010·Diabetes Technology & Therapeutics·Satish GargAnastasia Rodionova
Feb 18, 2009·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Sumeet R SinghHeather Bennett
Feb 27, 2007·Vascular Health and Risk Management·Anthony H Barnett
Aug 7, 2009·Wiener klinische Wochenschrift·Bernhard LudvikUNKNOWN Expertengruppe der Osterreichischen Diabetesgesellschaft
Mar 3, 2009·Medicina clínica·Arturo Lisbona Gil, Pedro Conthe Gutiérrez
Apr 17, 2008·Journal of Diabetes and Its Complications·A Enrique Caballero
Jul 23, 2008·The Cochrane Database of Systematic Reviews·Moshe VardiHaim Bitterman
Aug 2, 2007·Diabetes/metabolism Research and Reviews·J H DevriesT R Pieber
Jun 28, 2011·Diabetes Technology & Therapeutics·Stuart LittlePhilip Home
Sep 1, 2007·Expert Review of Endocrinology & Metabolism·Cecilia M Lansang, Laurence Kennedy
Aug 12, 2006·Journal of Child Neurology·Maria J HenwoodAdda Grimberg
Mar 29, 2006·Diabetes Care·Zachary T Bloomgarden
Nov 24, 2006·American Journal of Therapeutics·Athena Philis-TsimikasChris Walker
Mar 5, 2021·The Cochrane Database of Systematic Reviews·Bianca HemmingsenBernd Richter

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.